758 / 1631
RELEVANCE: RESPONSE BY IRC (ITT) (CO-PRIMARY ENDPOINT)
R
2
(n = 513)
R-chemo
(n = 517)
Co-Primary Endpoint:
CR/CRu at 120 weeks
Best CR/CRu
•
3-year DOR was 77% for R
2
vs 74% R-chemo (IRC)
•
Investigator results were consistent with IRC
Best ORR
53%
80%
100%
Response, %
59%
67%
60%
80%
100%
Response, %
Data cut-off31May2017.
Fowleret al. RELEVANCE: Phase III Randomized Study of LenalidomidePlus Rituximab (R
2
) Versus ChemotherapyPlus Rituximab,Followedby RituximabMaintenance,in PatientsWith Previously Untreated
FollicularLymphoma. Oral presentation at:American Society of ClinicalOncology meeting.2018; Jun 1-5; Chicago,IL. Abstract 7500.
84%
89%
80%
100%
Response, %
R
2
(n = 513)
R-chemo
(n = 517)
R
2
(n = 513)
R-chemo
(n = 517)
P
= 0.13
60% 48%
60%
40%
40%
40%
20%
20%
20%
0%
0%
0%